AIM: To determine whether the low C-peptide levels (< 50 pmol/l) produced by the pancreas for decades after onset of Type 1 diabetes have clinical significance. METHODS: We evaluated fasting C-peptide levels, duration of disease and age of onset in a large cross-sectional series (n = 1272) of people with Type 1 diabetes. We then expanded the scope of the study to include the relationship between C-peptide and HbA1c control (n = 1273), as well as diabetic complications (n = 324) and presence of hypoglycaemia (n = 323). The full range of C-peptide levels was also compared with 1,5-Anhydroglucitol, a glucose responsive marker. RESULTS: C-peptide levels declined for decades after diagnosis, and the rate of decline was significantly related to age of onset (P < 0.0001), after adjusting for disease duration. C-peptide levels > 10 pmol/l were associated with protection from complications (e.g. nephropathy, neuropathy, foot ulcers and retinopathy; P = 0.03). Low C-peptide levels were associated with poor metabolic control measured by HbA1c (P < 0.0001). Severe hypoglycaemia was associated with the lowest C-peptide levels compared with mild (P = 0.049) or moderate (P = 0.04) hypoglycaemia. All levels of measurable C-peptide were responsive to acute fluctuations in blood glucose levels as assessed by 1,5-Anhydroglucitol (P < 0.0001). CONCLUSIONS: Low C-peptide levels have clinical significance and appear helpful in characterizing groups at-risk for faster C-peptide decline, complications, poorer metabolic control and severe hypoglycaemia. Low C-peptide levels may be a biomarker for characterizing at-risk patients with Type 1 diabetes.
AIM: To determine whether the low C-peptide levels (< 50 pmol/l) produced by the pancreas for decades after onset of Type 1 diabetes have clinical significance. METHODS: We evaluated fasting C-peptide levels, duration of disease and age of onset in a large cross-sectional series (n = 1272) of people with Type 1 diabetes. We then expanded the scope of the study to include the relationship between C-peptide and HbA1c control (n = 1273), as well as diabetic complications (n = 324) and presence of hypoglycaemia (n = 323). The full range of C-peptide levels was also compared with 1,5-Anhydroglucitol, a glucose responsive marker. RESULTS:C-peptide levels declined for decades after diagnosis, and the rate of decline was significantly related to age of onset (P < 0.0001), after adjusting for disease duration. C-peptide levels > 10 pmol/l were associated with protection from complications (e.g. nephropathy, neuropathy, foot ulcers and retinopathy; P = 0.03). Low C-peptide levels were associated with poor metabolic control measured by HbA1c (P < 0.0001). Severe hypoglycaemia was associated with the lowest C-peptide levels compared with mild (P = 0.049) or moderate (P = 0.04) hypoglycaemia. All levels of measurable C-peptide were responsive to acute fluctuations in blood glucose levels as assessed by 1,5-Anhydroglucitol (P < 0.0001). CONCLUSIONS: Low C-peptide levels have clinical significance and appear helpful in characterizing groups at-risk for faster C-peptide decline, complications, poorer metabolic control and severe hypoglycaemia. Low C-peptide levels may be a biomarker for characterizing at-risk patients with Type 1 diabetes.
Authors: W J Kim; C Y Park; S E Park; E J Rhee; W Y Lee; K W Oh; S W Park; S W Kim; H S Park; Y J Kim; S J Song; H Y Ahn Journal: Diabet Med Date: 2012-09 Impact factor: 4.359
Authors: Denise L Faustman; Limei Wang; Yoshiaki Okubo; Douglas Burger; Liqin Ban; Guotong Man; Hui Zheng; David Schoenfeld; Richard Pompei; Joseph Avruch; David M Nathan Journal: PLoS One Date: 2012-08-08 Impact factor: 3.240
Authors: Jamie R J Inshaw; Antony J Cutler; Daniel J M Crouch; Linda S Wicker; John A Todd Journal: Diabetes Care Date: 2019-09-26 Impact factor: 19.112
Authors: Craig A Beam; Colleen MacCallum; Kevan C Herold; Diane K Wherrett; Jerry Palmer; Johnny Ludvigsson Journal: Diabetologia Date: 2016-10-04 Impact factor: 10.122
Authors: Ashley Pinckney; Mark R Rigby; Lynette Keyes-Elstein; Carol L Soppe; Gerald T Nepom; Mario R Ehlers Journal: Clin Ther Date: 2016-05-18 Impact factor: 3.393
Authors: Andrzej S Januszewski; Yoon Hi Cho; Mugdha V Joglekar; Ryan J Farr; Emma S Scott; Wilson K M Wong; Luke M Carroll; Yik W Loh; Paul Z Benitez-Aguirre; Anthony C Keech; David N O'Neal; Maria E Craig; Anandwardhan A Hardikar; Kim C Donaghue; Alicia J Jenkins Journal: Sci Rep Date: 2021-06-03 Impact factor: 4.379
Authors: Mary Courtney Moore; Shana O Warner; Yufei Dai; Nicole Sheanon; Marta Smith; Ben Farmer; Rebecca L Cason; Alan D Cherrington; Jason J Winnick Journal: JCI Insight Date: 2021-06-22